Gladius Capital Management LP bought a new position in Enfusion, Inc. (NYSE:ENFN – Free Report) in the 2nd quarter, HoldingsChannel reports. The fund bought 26,755 shares of the company’s stock, valued at approximately $228,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Scalar Gauge Management LLC purchased a new stake in shares of Enfusion during the fourth quarter worth $1,993,000. Wasatch Advisors LP raised its holdings in shares of Enfusion by 34.2% during the first quarter. Wasatch Advisors LP now owns 792,083 shares of the company’s stock worth $7,327,000 after acquiring an additional 201,771 shares in the last quarter. Brown Capital Management LLC raised its holdings in shares of Enfusion by 6.5% during the fourth quarter. Brown Capital Management LLC now owns 11,817,661 shares of the company’s stock worth $114,631,000 after acquiring an additional 724,502 shares in the last quarter. Azora Capital LP purchased a new stake in shares of Enfusion during the fourth quarter worth $134,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Enfusion during the first quarter worth $122,000. Institutional investors and hedge funds own 81.05% of the company’s stock.
Enfusion Price Performance
NYSE ENFN remained flat at $8.08 during trading on Friday. The company’s stock had a trading volume of 460,998 shares, compared to its average volume of 376,930. Enfusion, Inc. has a one year low of $7.52 and a one year high of $10.45. The business’s 50 day simple moving average is $8.64 and its two-hundred day simple moving average is $8.94. The company has a market cap of $1.04 billion, a P/E ratio of 269.33, a P/E/G ratio of 2.15 and a beta of 0.92.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on Enfusion
Insider Buying and Selling at Enfusion
In other Enfusion news, Director Deirdre Somers sold 4,629 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $8.40, for a total transaction of $38,883.60. Following the transaction, the director now directly owns 43,312 shares in the company, valued at $363,820.80. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Enfusion news, Director Deirdre Somers sold 4,629 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $8.40, for a total transaction of $38,883.60. Following the transaction, the director now directly owns 43,312 shares in the company, valued at $363,820.80. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $8.11, for a total value of $147,934.51. Following the completion of the transaction, the insider now owns 198,913 shares in the company, valued at $1,613,184.43. The disclosure for this sale can be found here. Insiders have sold a total of 36,318 shares of company stock worth $296,688 over the last three months. Corporate insiders own 36.44% of the company’s stock.
Enfusion Company Profile
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Recommended Stories
- Five stocks we like better than Enfusion
- What is the S&P/TSX Index?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- 3 REITs to Buy and Hold for the Long Term
- MarketBeat Week in Review – 8/12 – 8/16
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Want to see what other hedge funds are holding ENFN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enfusion, Inc. (NYSE:ENFN – Free Report).
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.